Alternative Energy - Alternative Fuels and Chemicals: Industry Tidbit

Gen2 Biofuel Feedstocks: The Coming Surge in Energy Crops and Cellulosic Sugars

As energy investors know well, it is much better to own the oil than to refine it. In other words, the bulk of the value is in the upstream of the value chain. Next-generation (Gen2) biofuels and renewable chemicals have a somewhat different market dynamic – there is considerable value in the proprietary IP for processing – but feedstock providers can nonetheless capture a sizable share of the economics. With this in mind, following recent channel checks and in the context of our Gen2 coverage, in this report we highlight the addressable market for two subsets of Gen2 biofuel feedstocks: energy crops and cellulosic sugars.

The rationale for energy crops. Because cellulosic biomass is a non-food material that has little or no intrinsic value, the cost structure for Gen2 biofuels using these feedstocks is immune to day-to-day volatility in the agricultural market. Cellulosic biomass, however, is not without its constraints. Current sources of biomass, such as forestry residue (wood chips, etc.) and agricultural waste (corn stover, sugarcane bagasse, etc.), are typically limited in scale. For example, even in such biomass-rich areas as the U.S. Southeast, where wood chips are plentiful, their availability within a reasonable radius from a biofuel plant is often constrained. This helps explain why cellulosic biofuel plants (such as KiOR’s biocrude plants) are typically being designed with much lower production capacity than modern corn ethanol plants: 20-40 million gallons vs. 100+ million gallons. In addition, these sources of biomass are byproducts derived from other processes and are, therefore, subject to supply disruptions.

In contrast to cellulosic biomass, dedicated energy crops are specifically designed to be used in biofuel applications. Energy crops offer five key advantages: (1) high yield density: increasing crop yields per acre shortens the collection radius for biofuel plants; (2) high net energy balance: compared to corn (and, to a lesser extent, sugarcane), energy crops need less energy input per unit of energy output; (3) low input requirements: reduced water and fertilizer needs are a key source of savings; (4) ability to grow on marginal land: energy crops can grow in a broad range of environments, including those not well-suited for most food crops; and (5) customization potential: energy crops have the potential to be tailored for specific production and refining processes. On a side note: above and beyond biofuels, energy crops can also be well-suited for use in biomass-based power generation.

Types of energy crops. Most plants that can serve as energy crops are already used commercially in their natural form, but a key aspect of energy crops is that they are specially tailored (via genetic modification or otherwise) for biofuel applications. The optimal crop for any given biofuel project can depend on (1) the specific end product and (2) geography and climate patterns, though the latter – as noted above – is often flexible. Here are some examples. Jatropha, a source of oil (in place of soybean or palm oil) for production of renewable diesel and jet fuel, is a drought-resistant perennial that is especially well suited for Central/South America, where it is a native crop. SG Biofuels is working to develop jatropha in Guatemala and Brazil, though potential opportunities exist across the Southern Hemisphere. (The adjacent photo shows jatropha in Kenya.) SG Biofuels notes that its best cultivars can currently produce crude jatropha oil for $1.40/gal, and the long-term target is $0.75/gal. Sorghum – the sweet variety for conventional ethanol plants and the high-biomass variety for cellulosic ethanol plants – is capable of growing on ~80% of the world’s agricultural lands, with some developers focusing on the U.S. market (e.g., Chromatin) and others on Brazil (e.g., NexSteppe). Miscanthus, a perennial grass that can be used for ethanol, is native to Africa and South Asia; Mendel Biotechnology has been working to develop it domestically, for example, in Ohio on land reclaimed from coal mining by Oxford Resource Partners. It is also possible to engineer energy crops to have internal enzymes, making it easier to break down their cellulose, as Agrivida has done with corn stover and switchgrass.

Please read domestic and foreign disclosure/risk information beginning on page 3 and Analyst Certification on page 3.
The rationale for cellulosic sugars. For fermentation-based Gen2 companies – especially those specializing in renewable chemicals and other high-value end products – sugar is a crucial feedstock. While sugar can obviously be easily produced from sugarcane and some other food crops, cost is clearly a limiting factor amid a global bull market for agricultural commodities. This is why companies such as Amyris and Solazyme (which currently rely on sugarcane) and Gevo (which is using corn) have indicated their desire to eventually shift towards alternative feedstocks – once they become available on a commercial scale. Whereas cellulosic material – either waste biomass or energy crops – can be used directly in thermochemical production of biofuels (e.g., gasification or catalytic processing), for it to be used in fermentation there needs to be an intermediate step. This involves breaking down the cellulose so that the sugar can be extracted. Some biofuel producers take a vertically integrated approach and, therefore, aim to do this in-house. However, there is a small but growing subset of companies that are developing cellulosic sugars for sale to third parties, either via direct product sales or technology licensing.

Production options for cellulosic sugars. The process of converting cellulosic material into fermentable sugars is called saccharification, and it can be performed via several types of hydrolysis. When the material is saccharified, separating the carbohydrates, the sugar is released. The main byproduct, lignin, can be used to provide the energy for the production facility and/or serves as an additional source of revenue. There are three main types of hydrolysis, which we discuss below. To be clear, all three of these are development-stage technologies that have yet to scale up commercially.

- **Acid hydrolysis.** This process entails using acid to break down the cellulose. For example, HCL CleanTech, as its name suggests, aims to use concentrated hydrochloric acid. The company has projected that the cost of its cellulosic sugars will be at least 17% lower than the cost of corn mill sugars. Weyland, based in Norway, estimates that its acid-based process enables 98.5% of the acid input to be recycled, thus creating cost savings. SucreSource, a subsidiary of cellulosic ethanol developer BlueFire Renewables, also uses acid.

- **Enzymatic hydrolysis.** This process uses enzymes, probably the technology that is most commonly associated with cellulosic biofuels. EdeniQ plans to provide sugars via an enzymatic platform as part of a broader suite of services for cellulosic biofuel producers. In addition, of course, plenty of cellulosic biofuel producers are themselves developing enzymatic technology, either wholly in-house or in partnership with enzyme providers (such as logen’s collaboration with Codexis). Historically, the downside of enzymes has been their high cost, with Agrivida estimating that they can add $0.50-0.75/gal to the cost of cellulosic biofuels, though next-generation biocatalyst technology helps address the cost issue.

- **Supercritical hydrolysis.** This process, pioneered by Renmatix, uses pressure and heat to bring water to a supercritical state, in which it behaves like both a liquid and a gas. Cellulose becomes soluble in the supercritical fluid, allowing the sugar separation to take place. The company has said that its first commercial facility will be able to produce 100,000 dry tons of sugars each year at a cost that is competitive with Brazilian sugarcane. We already noted that many Gen2 biofuel producers are interested in sourcing cellulosic sugars, and in this context, Amyris has said that it plans to buy Renmatix’s sugars upon commercialization.

Finally, there is one more approach to production of sugars, but this one falls outside the cellulosic arena altogether. Developed by Proterro, this biosynthetic process combines an engineered photosynthetic microorganism with a high-density, modular solid-phase bioreactor to produce sucrose. Instead of breaking down cellulosic biomass, these cellulosic sugars are produced by combining water, carbon dioxide, sunlight, and nutrients.

### Company Citations

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Ticker</th>
<th>Exchange</th>
<th>Currency</th>
<th>Closing Price</th>
<th>RJ Rating</th>
<th>RJ Entity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amyris, Inc.</td>
<td>AMRS</td>
<td>NASDAQ</td>
<td>$</td>
<td>11.52</td>
<td>1</td>
<td>RJ &amp; Associates</td>
</tr>
<tr>
<td>Codexis, Inc.</td>
<td>CDXS</td>
<td>NASDAQ</td>
<td>$</td>
<td>5.44</td>
<td>3</td>
<td>RJ &amp; Associates</td>
</tr>
<tr>
<td>Gevo, Inc.</td>
<td>GEVO</td>
<td>NASDAQ</td>
<td>$</td>
<td>5.90</td>
<td>2</td>
<td>RJ &amp; Associates</td>
</tr>
<tr>
<td>KiOR, Inc.</td>
<td>KIOR</td>
<td>NASDAQ</td>
<td>$</td>
<td>9.25</td>
<td>2</td>
<td>RJ &amp; Associates</td>
</tr>
<tr>
<td>Oxford Resource Partners L.P.</td>
<td>OXF</td>
<td>NYSE</td>
<td>$</td>
<td>17.38</td>
<td>2</td>
<td>RJ &amp; Associates</td>
</tr>
<tr>
<td>Solazyme, Inc.</td>
<td>SZYM</td>
<td>NASDAQ</td>
<td>$</td>
<td>11.14</td>
<td>2</td>
<td>RJ &amp; Associates</td>
</tr>
</tbody>
</table>

Notes: Prices are as of the most recent close on the indicated exchange and may not be in US$. See Disclosure section for rating definitions. Stocks that do not trade on a U.S. national exchange may not be approved for sale in all U.S. states. NC=not covered.
Important Investor Disclosures
Raymond James & Associates (RJA) is a FINRA member firm and is responsible for the preparation and distribution of research created in the United States. Raymond James & Associates is located at The Raymond James Financial Center, 880 Carillon Parkway, St. Petersburg, FL 33716, (727) 567-1000. Non-U.S. affiliates, which are not FINRA member firms, include the following entities which are responsible for the creation and distribution of research in their respective areas: In Canada, Raymond James Ltd., Suite 2200, 925 West Georgia Street, Vancouver, BC V6C 3L2, (604) 659-8200; In Latin America, Raymond James Latin America, Ruta 8, km 17, 500, 91600 Montevideo, Uruguay, 00598 2 518 2033; In Europe, Raymond James European Equities, 40, rue La Boetie, 75008, Paris, France, +33 1 45 61 64 90.

This document is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The securities discussed in this document may not be eligible for sale in some jurisdictions. This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Investors should consider this report as only a single factor in making their investment decision.

Investing in securities of issuers organized outside of the U.S., including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of, the U.S. Securities and Exchange Commission. There may be limited information available on such securities. Investors who have received this report may be prohibited in certain states or other jurisdictions from purchasing the securities mentioned in this report. Please ask your Financial Advisor for additional details. The information provided is as of the date above and subject to change, and it should not be deemed a recommendation to buy or sell any security. Certain information has been obtained from third-party sources we consider reliable, but we do not guarantee that such information is accurate or complete. Persons within the Raymond James family of companies may have information that is not available to the contributors of the information contained in this publication. Raymond James, including affiliates and employees, may execute transactions in the securities listed in this publication that may not be consistent with the ratings appearing in this publication. Additional information is available on request.

Analyst Information
Registration of Non-U.S. Analysts: The analysts listed on the front of this report who are not employees of Raymond James & Associates, Inc., are not registered/qualified as research analysts under FINRA rules, are not associated persons of Raymond James & Associates, Inc., and are not subject to NASD Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public companies, and trading securities held by a research analyst account.

Analyst Holdings and Compensation: Equity analysts and their staffs at Raymond James are compensated based on a salary and bonus system. Several factors enter into the bonus determination including quality and performance of research product, the analyst’s success in rating stocks versus an industry index, and support effectiveness to trading and the retail and institutional sales forces. Other factors may include but are not limited to: overall ratings from internal (other than investment banking) or external parties and the general productivity and revenue generated in covered stocks.

The views expressed in this report accurately reflect the personal views of the analyst(s) covering the subject securities. No part of said person’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. In addition, said analyst has not received compensation from any subject company in the last 12 months.

Ratings and Definitions
Raymond James & Associates (U.S.) definitions
Strong Buy (SB1) Expected to appreciate, produce a total return of at least 15%, and outperform the S&P 500 over the next six to 12 months. For higher yielding and more conservative equities, such as REITs and certain MLPs, a total return of at least 15% is expected to be realized over the next 12 months.
Outperform (MO2) Expected to appreciate and outperform the S&P 500 over the next 12-18 months. For higher yielding and more conservative equities, such as REITs and certain MLPs, an Outperform rating is used for securities where we are comfortable with the relative safety of the dividend and expect a total return modestly exceeding the dividend yield over the next 12-18 months.
Market Perform (MP3) Expected to perform generally in line with the S&P 500 over the next 12 months.
Underperform (MU4) Expected to underperform the S&P 500 or its sector over the next six to 12 months and should be sold.
Suspended (S) The rating and price target have been suspended temporarily. This action may be due to market events that made coverage impracticable, or to comply with applicable regulations or firm policies in certain circumstances, including when Raymond James may be providing investment banking services to the company. The previous rating and price target are no longer in effect for this security and should not be relied upon.
Raymond James Ltd. (Canada) definitions

**Strong Buy (SB1)** The stock is expected to appreciate and produce a total return of at least 15% and outperform the S&P/TSX Composite Index over the next six months.

**Outperform (MO2)** The stock is expected to appreciate and outperform the S&P/TSX Composite Index over the next twelve months.

**Market Perform (MP3)** The stock is expected to perform generally in line with the S&P/TSX Composite Index over the next twelve months and is potentially a source of funds for more highly rated securities.

**Underperform (MU4)** The stock is expected to underperform the S&P/TSX Composite Index or its sector over the next six to twelve months and should be sold.

Raymond James Latin American rating definitions

**Strong Buy (SB1)** Expected to appreciate and produce a total return of at least 25.0% over the next twelve months.

**Outperform (MO2)** Expected to appreciate and produce a total return of between 15.0% and 25.0% over the next twelve months.

**Market Perform (MP3)** Expected to perform in line with the underlying country index.

**Underperform (MU4)** Expected to underperform the underlying country index.

**Suspended (S)** The rating and price target have been suspended temporarily. This action may be due to market events that made coverage impracticable, or to comply with applicable regulations or firm policies in certain circumstances, including when Raymond James may be providing investment banking services to the company. The previous rating and price target are no longer in effect for this security and should not be relied upon.

Raymond James European Equities rating definitions

**Strong Buy (1)** Expected to appreciate, produce a total return of at least 15%, and outperform the Stoxx 600 over the next 6 to 12 months.

**Outperform (2)** Expected to appreciate and outperform the Stoxx 600 over the next 12 months.

**Market Perform (3)** Expected to perform generally in line with the Stoxx 600 over the next 12 months.

**Underperform (4)** Expected to underperform the Stoxx 600 or its sector over the next 6 to 12 months.

In transacting in any security, investors should be aware that other securities in the Raymond James research coverage universe might carry a higher or lower rating. Investors should feel free to contact their Financial Advisor to discuss the merits of other available investments.

**Rating Distributions**

<table>
<thead>
<tr>
<th></th>
<th>Coverage Universe Rating Distribution</th>
<th>Investment Banking Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RJA</td>
<td>RIL</td>
</tr>
<tr>
<td>Strong Buy and Outperform (Buy)</td>
<td>58%</td>
<td>71%</td>
</tr>
<tr>
<td>Market Perform (Hold)</td>
<td>36%</td>
<td>28%</td>
</tr>
<tr>
<td>Underperform (Sell)</td>
<td>6%</td>
<td>1%</td>
</tr>
</tbody>
</table>

**Suitability Categories (SR)**

For stocks rated by Raymond James & Associates only, the following Suitability Categories provide an assessment of potential risk factors for investors. Suitability ratings are not assigned to stocks rated Underperform (Sell). Projected 12-month price targets are assigned only to stocks rated Strong Buy or Outperform.

**Total Return (TR)** Lower risk equities possessing dividend yields above that of the S&P 500 and greater stability of principal.

**Growth (G)** Low to average risk equities with sound financials, more consistent earnings growth, possibly a small dividend, and the potential for long-term price appreciation.

**Aggressive Growth (AG)** Medium or higher risk equities of companies in fast growing and competitive industries, with less predictable earnings and acceptable, but possibly more leveraged balance sheets.

**High Risk (HR)** Companies with less predictable earnings (or losses), rapidly changing market dynamics, financial and competitive issues, higher price volatility (beta), and risk of principal.

**Venture Risk (VR)** Companies with a short or unprofitable operating history, limited or less predictable revenues, very high risk associated with success, and a substantial risk of principal.

**Raymond James Relationship Disclosures**

Raymond James expects to receive or intends to seek compensation for investment banking services from the subject companies in the next three months.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codexis, Inc.</td>
<td>Raymond James &amp; Associates makes a NASDAQ market in shares of CDXS.</td>
</tr>
</tbody>
</table>
Stock Charts, Target Prices, and Valuation Methodologies

Valuation Methodology: The Raymond James methodology for assigning ratings and target prices includes a number of qualitative and quantitative factors including an assessment of industry size, structure, business trends and overall attractiveness; management effectiveness; competition; visibility; financial condition, and expected total return, among other factors. These factors are subject to change depending on overall economic conditions or industry- or company-specific occurrences. Only stocks rated Strong Buy (SB1) or Outperform (MO2) have target prices and thus valuation methodologies.

Risk Factors

General Risk Factors: Following are some general risk factors that pertain to the projected target prices included on Raymond James research:
(1) Industry fundamentals with respect to customer demand or product/service pricing could change and adversely impact expected revenues and earnings; (2) Issues relating to major competitors or market shares or new product expectations could change investor attitudes toward the sector or this stock; (3) Unforeseen developments with respect to the management, financial condition or accounting policies or practices could alter the prospective valuation; or (4) External factors that affect the U.S. economy, interest rates, the U.S. dollar or major segments of the economy could alter investor confidence and investment prospects. International investments involve additional risks such as currency fluctuations, differing financial accounting standards, and possible political and economic instability.

Additional Risk and Disclosure information, as well as more information on the Raymond James rating system and suitability categories, is available at ricapitalmarkets.com/SearchForDisclosures_main.asp. Copies of research or Raymond James’ summary policies relating to research analyst independence can be obtained by contacting any Raymond James & Associates or Raymond James Financial Services office (please see raymondjames.com for office locations) or by calling 727-567-1000, toll free 800-237-5643 or sending a written request to the Equity Research Library, Raymond James & Associates, Inc., Tower 3, 6th Floor, 880 Carillon Parkway, St. Petersburg, FL 33716.
Non-Brazil-based analysts writing Brazil research and or making sales efforts with the same are released from these APIMEC requirements as stated in Art. 20 of CVM Instruction #483, but abide by recognized Codes of Conduct, Ethics and Practices that comply with Articles 17, 18, and 19 of CVM Instruction #483.

Proprietary Rights Notice: By accepting a copy of this report, you acknowledge and agree as follows:

This report is provided to clients of Raymond James only for your personal, noncommercial use. Except as expressly authorized by Raymond James, you may not copy, reproduce, transmit, sell, display, distribute, publish, broadcast, circulate, modify, disseminate or commercially exploit the information contained in this report, in printed, electronic or any other form, in any manner, without the prior express written consent of Raymond James. You also agree not to use the information provided in this report for any unlawful purpose.

This report and its contents are the property of Raymond James and are protected by applicable copyright, trade secret or other intellectual property laws (of the United States and other countries). United States law, 17 U.S.C. Sec.501 et seq, provides for civil and criminal penalties for copyright infringement.